BARLETTA, FRANCESCO MARIA
 Distribuzione geografica
Continente #
EU - Europa 1.714
NA - Nord America 1.579
AS - Asia 1.130
SA - Sud America 159
Continente sconosciuto - Info sul continente non disponibili 121
AF - Africa 26
OC - Oceania 1
Totale 4.730
Nazione #
US - Stati Uniti d'America 1.456
RU - Federazione Russa 959
SG - Singapore 432
IT - Italia 333
CN - Cina 328
BR - Brasile 115
HK - Hong Kong 107
VN - Vietnam 97
SE - Svezia 90
DE - Germania 80
CA - Canada 69
GB - Regno Unito 56
BD - Bangladesh 54
FR - Francia 50
FI - Finlandia 37
IN - India 37
NL - Olanda 25
MX - Messico 22
PL - Polonia 22
AR - Argentina 20
ES - Italia 15
CR - Costa Rica 13
ZA - Sudafrica 12
AT - Austria 11
BE - Belgio 10
JP - Giappone 10
EC - Ecuador 8
TR - Turchia 8
UA - Ucraina 7
IQ - Iraq 6
IR - Iran 6
AE - Emirati Arabi Uniti 5
CO - Colombia 5
LT - Lituania 5
MA - Marocco 5
MY - Malesia 5
PH - Filippine 5
SA - Arabia Saudita 5
NP - Nepal 4
TN - Tunisia 4
VE - Venezuela 4
CZ - Repubblica Ceca 3
GT - Guatemala 3
HN - Honduras 3
ID - Indonesia 3
IE - Irlanda 3
JM - Giamaica 3
NI - Nicaragua 3
PY - Paraguay 3
UZ - Uzbekistan 3
DZ - Algeria 2
KG - Kirghizistan 2
NO - Norvegia 2
PE - Perù 2
PK - Pakistan 2
PR - Porto Rico 2
AL - Albania 1
AM - Armenia 1
AU - Australia 1
CH - Svizzera 1
CL - Cile 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DM - Dominica 1
GD - Grenada 1
GE - Georgia 1
GR - Grecia 1
HT - Haiti 1
IL - Israele 1
JO - Giordania 1
KE - Kenya 1
KH - Cambogia 1
KR - Corea 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
OM - Oman 1
PS - Palestinian Territory 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 4.610
Città #
Ashburn 214
Moscow 173
Singapore 171
Dallas 148
San Jose 131
Milan 115
Hong Kong 104
New York 82
Council Bluffs 62
Beijing 55
Shanghai 51
Los Angeles 48
Santa Clara 41
Phoenix 35
Hefei 30
Ho Chi Minh City 30
Munich 30
Rome 26
Lauterbourg 25
Hanoi 22
Orem 19
Turku 19
Frankfurt am Main 18
Princeton 18
Warsaw 18
Chennai 16
Boardman 15
Lawrence 15
Buffalo 14
Chicago 14
Montreal 14
North Bergen 14
São Paulo 14
Brooklyn 12
Denver 12
Memphis 12
Atlanta 11
Helsinki 11
Nuremberg 11
Amsterdam 10
Tokyo 10
Houston 9
London 9
Mexico City 9
Miano 9
Naples 9
Stockholm 9
Guangzhou 8
Johannesburg 8
Manchester 8
Da Nang 7
San José 7
Seattle 7
Turin 7
Columbus 6
Miami 6
San Francisco 6
Brussels 5
Chongqing 5
Dalian 5
Lappeenranta 5
Las Vegas 5
Mumbai 5
Poplar 5
Querétaro 5
The Dalles 5
Toronto 5
Vancouver 5
Barnet 4
Cerano 4
Guayaquil 4
Kuala Lumpur 4
Milwaukee 4
Monza 4
Oudehaske 4
Porto Alegre 4
Pune 4
Valencia 4
Ankara 3
Belo Horizonte 3
Biên Hòa 3
Bologna 3
Boston 3
Catania 3
Cesano Boscone 3
City of London 3
Dhaka 3
Dublin 3
Edinburgh 3
Figino 3
Heredia 3
Jackson 3
Madrid 3
Manassas 3
Molfetta 3
Newark 3
Oklahoma City 3
Omaha 3
Paderborn 3
Palermo 3
Totale 2.175
Nome #
Prognostic impact of mitral regurgitation changes after TAVI 231
A NOVEL MODEL INTEGRATING CLINICAL, MP-MRI, AND EPIGENOMIC FEATURES TO PREDICT LYMPH NODE INVASION IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY AND PELVIC LYMPH NODE DISSECTION 188
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02 175
How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series 174
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard 164
Impact of Pacemaker Implantation After Transcatheter Aortic Valve Replacement on Long-Term Survival in Patients With Bicuspid Aortic Valve 156
Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer – a systematic review and meta-analysis 147
Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool 142
Impact of Early Dorsal Venous Complex Ligation on Urinary Continence Recovery after Robot-assisted Radical Prostatectomy: Results from a Phase 3 Randomized Controlled Trial 138
Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era? 138
Defining the optimal target-to-background ratio to identify positive lymph nodes in prostate cancer patients undergoing robot-assisted [99mTc]Tc-PSMA radioguided surgery: updated results and ad interim analyses of a prospective phase II study 136
Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis 134
Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study 133
Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series 132
Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series 127
Impact of prostate MRI central review over the diagnostic performance of MRI-targeted biopsy: should we routinely ask for an expert second opinion? 126
A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment 124
Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions 122
External Validation of Nomograms for the Identification of Pelvic Nodal Dissection Candidates Among Prostate Cancer Patients with Negative Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography 116
Assessing the need for systematic biopsies in addition to targeted biopsies according to the characteristics of the index lesion at mpMRI. Results from a large, multi-institutional database 116
ASSOCIATION BETWEEN BRCA 1/2 POLYMORPHISMS AND DISEASE AGGRESSIVENESS IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 116
Diagnostic and prognostic factors in patients with prostate cancer: A systematic review protocol 114
DNA methylation alterations in prostate cancer: from diagnosis to treatment 113
Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer 110
ASSOCIATION BETWEEN POLYMORPHISMS OF HOMOLOGOUS RECOMBINATION RAD51B AND DISEASE RECURRENCE IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 107
Reducing the Risk of Postoperative Complications After Robot-assisted Radical Prostatectomy in Prostate Cancer Patients: Results of an Audit and Feedback Intervention Following the Implementation of Prospective Data Collection 105
Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy 100
Tailored use of PSA density according to multiparametric MRI index lesion location: results of a large, multi-institutional series 97
Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial 96
Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy 95
Left Atrial Dynamics During Exercise in Mitral Regurgitation of Primary and Secondary Origin: Pathophysiological Insights by Exercise Echocardiography Combined With Gas Exchange Analysis 90
The added value of artificial intelligence using Quantib Prostate for the detection of prostate cancer at multiparametric magnetic resonance imaging 89
Extra- Mitral Valve Cardiac Involvement in Patients With Primary Mitral Regurgitation Undergoing Transcatheter Edgeto- Edge Repair 86
Utility of MRI perilesional biopsy in prostate cancer: impact of the Prostate Imaging-Reporting and Data System and biopsy history 85
Prognostic Significance of Flail Mitral Leaflet in Transcatheter Edge-to-Edge Repair for Primary Mitral Regurgitation 78
Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate 70
Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score 31
Surgical Management of PSMA PET-Positive Lymph Nodes in Prostate Cancer 26
Prognostic value of PSMA PET/CT-based in predicting biochemical recurrence after radical prostatectomy in miN0 patients 24
Nodal maximum standardised uptake value improves PSMA-PET/CT-based nodal staging in intermediate- and high-risk prostate cancer 20
Years of Life Lost From Metastatic Prostate Cancer According to Treatment Era and Race/Ethnicity 20
Serenoa Repens–Lycopene–Selenium and Epilobium–Palmitoylethanolamide–Calendula after transperineal prostate biopsy: a tertiary single center experience 19
Patient selection for prostate cancer focal therapy guided by mpMRI–PSMA PET concordance and pathology review 18
Multicentre validation of the PRECISE scoring system for prostate MRI during active surveillance 17
PSMA Radio-guided Surgery to Identify Lymph Node Metastases in Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Phase 2 Prospective Study 15
Years of life lost and mortality rates from metastatic prostate cancer in contemporary African Americans vs. Caucasians 15
Re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer 14
Incidence and Predictors of Acute Kidney Injury and Acute Kidney Disease After Robot-assisted Radical Prostatectomy in Prostate Cancer Patients 12
Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy 11
Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy among Patients with Adverse Pathology at Radical Prostatectomy 7
PD35-02 WHEN IS NEOADJUVANT ANDROGEN DEPRIVATION THERAPY BENEFICIAL FOR HIGHLY AGGRESSIVE PROSTATE CANCER CANDIDATES TO RADICAL PROSTATECTOMY? IMPLICATIONS FOR MULTI-MODAL TAILORED APPROACHES AND TRIALS DESIGN 6
PD35-01 WHICH PATIENTS WITH CN1 DISEASE AT PET/CT ARE AFFECTED BY SYSTEMIC DISEASE? IMPLICATIONS FOR TAILORED TREATMENT APPROACHES BASED ON A LARGE MULTI-INSTITUTIONAL SERIES 5
Totale 4.730
Categoria #
all - tutte 19.712
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.712


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202217 0 0 0 11 0 0 1 2 0 0 0 3
2022/2023141 37 29 12 8 3 15 5 18 1 0 6 7
2023/2024217 4 14 26 19 20 51 1 27 5 16 13 21
2024/2025694 40 15 13 22 39 57 104 79 46 26 123 130
2025/20262.827 155 155 140 333 232 79 203 272 839 188 129 102
2026/2027818 132 110 230 346 0 0 0 0 0 0 0 0
Totale 4.730